免疫检查点抑制剂治疗非小细胞肺癌新进展

摘要/Abstract

摘要： 免疫疗法被喻为恶性肿瘤最有前景的治疗方法，免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）治疗肿瘤的方法更是以其显著的临床疗效而备受瞩目。ICIs可在晚期黑色素瘤、肾癌、肺癌、头颈癌、膀胱癌、乳腺癌等多个适应证显示疗效，其在非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗中更是被视为革命性的突破。随着研究的不断深入，目前ICIs在临床试验中也已获得突破性的研究进展，但是ICIs的毒性、标志物的设定以及联合疗法给患者带来的诸多问题也是不容忽视的。本研究拟就近几年ICIs临床治疗NSCLC的最新进展作一综述，以期为临床治疗NSCLC提供借鉴和参考。

Abstract: Immunotherapy has been referred to as the most promising treatment for malignant tumors， and immune checkpoint inhibitors(ICIs) have been attracting attention for their clinical efficacy. ICIs can be used in a variety of indications for advanced melanoma，kidney cancer， lung cancer， head and neck cancer，bladder cancer，breast cancer， etc.，and ICIs have gained breakthrough in clinical treatment for non-small cell lung cancer (NSCLC).With the deepening of research，ICIs have also made breakthroughs in clinical trials， but the toxicity of ICIs， the setting of biomarker， and the problems that combination therapies bring to patients can not be ignored.So， this study intends to review the recent progress in the clinical treatment of NSCLC in ICIs， in order to provide reference for clinical treatment of NSCLC.

姜攀. 免疫检查点抑制剂治疗非小细胞肺癌新进展[J]. .

JIANG Pan. New Progress of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer[J]. .

参考文献

[1] Seetharamu N, Budman D R, Sullivan K M. Immune checkpoint inhibitors in lung cancer: past, present and future[J]. Future Oncol, 2016, 12(9):1151-1163.
[2] Giroux L E, Dumenil C, Julie C, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges[J]. Eur J Cancer, 2017,78(6):16-23.
[3] Vogel I, Kasran A, Cremer J, et al. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity[J]. Eur J Immunol, 2015, 45(6):1832-1841.
[4] Lynch TJ, Bondarenko I, Luft A,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small cell lung cancer: results from a randomized, double-blind, multicenter phase II study[J].J Clin Oncol,2012,30 (17) :2046-2054.
[5] Zatloukal P,Heo DS,Park K,et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care following first-line platinum-based therapy in patients with advanced non-small cell lung [J].J Clin Oncol,2009,27(15-suppl):8071.
[6] Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy [J]. Cancer Cell, 2015, 27(4): 450-461.
[7] Galon J, Fox B A, Bifulco C B, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015[J]. J Transl Med ,2016 ,14 (1) :273
[8] Peters S, Creelan B, Hellmann MD, et al. Impact of Tumor Mutation Burden on the Efficacy of First-LineNiv in Stage IV or Recurrent Non-Small Cell Lung Cancer:An Exploratory Analysis of CheckMate 026[C]. Washington: AACR Annual Meeting, 2017,77(Suppl 13): Abstract CT082.
[9] Hirsch FR,McElhinny A,Stanforth D,et al.PD-L1 Immunohistochemistry Assays for Lung Cancer：Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.[J] J Thorac Oncol,2017,12(2):208-222.
[10] Brahmer J, Horn L, Jackman D, et al. Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors [C] . Washington: AACR Annual Meeting ,2017,77(Suppl 13): Abstract CT077.
[11] Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med,2015,372(21): 2018-2028．
[12] Reck M, Rodriguez- Abreu D, Robinson A G, et al. Pembrolizumab versus Chemotherapy for PD- L1- Positive Non Small- Cell Lung Cancer [J]. N Engl J Med, 2016, 375 (19): 1823- 1833.
[13] Herbst RS,Soria JC,Kowanetz M,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature,2014,515( 7528): 563-567.
[14] Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846.
[15] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.[J]. Lancet, 2017, 389(10066):255-265.
[16] Diggs L P, Hsueh E C. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response[J]. Biomarker Res, 2017, 5(1):12.
[17] Planchard D, Yokoi T, McCleod M J, et al. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study[J]. Clin Lung Cancer. 2016;17(3):232-236.e1
[18] Heery C R, O’Sullivancoyne G, Madan R A, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial[J]. Lancet Oncol, 2017, 18(5):587-598.
[19] Jochems C, Hodge J W, Fantini M, et al. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody[J]. Int J Cancer, 2017, 141(3):583-593.
[20] Gulley J L, Rajan A, Spigel D R, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2017, 18:599-610
[21] Reck M, Degreen HP , Rose AL, et al. Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial[J].J Clin Oncol, 2016, 34 (suppl): abstr TPS9105
[22] Hellmann M D, Rizvi N A, Goldman J W, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J]. Lancet Oncol, 2017, 18(1):31-41.
[23] Patnaik A, Sociniski M, Gubens M, et al.Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE- 021 cohort D[J].J Clin Oncol,2015,33(Suppl):abstr8011.
[24] Antonia S,Goldberg S B,Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J]. Lancet Oncol, 2016, 17(3):299-308.
[25] Mok T, Schmid P, Jr G D C, et al. First-line durvalumab plus tremelimumab vs platinum-based chemotherapy for advanced/metastatic nsclc: phase 3 neptune study [J]. J Thorac Oncol, 2017, 12(S1): S568.
[26] Rizvi N, Barlesi F, Brahmer J, et al. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC[J]. J Immunother Cancer, 2015, 3(Suppl 2):P171.
[27] Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11):1497-1508.
[28] Papadimitrakopoulou V, Gadgeel SM, Borghaei H, et al. First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G [J]. J Clin Oncol,2017,35(Suppl):abstr 9094.
[29] Papadimitrakopoulou V, Cappuzzo F, Jotte RM, et al. Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC[J]. J Clin Oncol,2016,34(Suppl):abstr TPS9103.
[30] Yun Fan, Xiaoling Xu. Combination of anti-PD-1/PD-L1 antibodies with chemotherapy or CTL4 antibodies for first-line treatment of advanced lung cancer [J]. J Clin Oncol,2017,35(Suppl):abstr e20538.
[31] Partarrieu J. NSCLC patients respond best to salvage chemo if pre-treated with checkpoint inhibitors[R]. ELCC Annual Meeting ,Geneva, Switzerland, 2017
[32] Lin C, Chen X, Li M, et al . Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma[J]. Clin Lung Cancer ,2015, 16(5):e25-35
[33] Ahn M J, Sun J M, Lee S H, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer[J]. Expert Opin Drug Saf, 2017, 16(4):465-469.
[34] Rizvi N A, Antonia S J, Shepherd F A, et al. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy[J]. Int J Radiat Oncol Biol Phys, 2014, 90(5):S32-S32.
[35] Kanda S, Goto K, Shiraishi H, et al. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study[J]. Ann Oncol, 2016, 27(12):2242-2250.
[36]Yue E W, Sparks R, Polam P, et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology[J]. ACS Med Chem Lett, 2017, 8(5):486-491.
[37] Beatty G L, O''Dwyer P J, Clark J, et al. First-in-Human Phase 1 Study of the Oral Inhibitor of Indoleamine 2,3-dioxygenase-1 Epacadostat (INCB024360) in Patients With Advanced Solid Malignancies[J]. Clin Cancer Res,2017, 23(13):3269-3276.
[38] Gangadhar TC,Hamid O,Smith DC,et al. Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037[J]. Ann Oncol, 2016,27(suppl 6).
[39] Gangadhar TC, Schneider BJ, Bauer TM,et al.Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/ KEYNOTE-037.J Clin Oncol,2017,35(Suppl 15):9014.
[40]Naing A, Infante J R, Papadopoulos K P, et al. Abstract PR08: Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1[J]. Cancer Immunol Res, 2016, 4(Suppl 11):PR08-PR08.
[41] Lee Wong DJ, Schneider JG, Aljumaily R, et al.Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC[J].J Clin Oncol, 2017, 35 (suppl): abstr 9091.
[42] Willingham S, Hotson A, Ho P, et al. Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies[J]. Cancer Immunol Res, 2016, 4(Suppl 11):PR04-PR04.
[43] Fong L, Forde P M, Powderly J D,et al. Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients [J].J Clin Oncol, 2017, 35 (suppl): abstr 3004.
[44] Shaverdian N, Lisberg A E, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895-903.
[45] Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?[J]. Bmc Medicine, 2017, 15(1):55-61.
[46] AZ.AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer[EB/OL].https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-reports-initial-results-from-the-ongoing-mystic-trial-in-stage-iv-lung-cancer-27072017.html
[47] Ledford H. Promising cancer drugs may speed tumours in some patients[J]. Nature, 2017, 544(7648):13.

快速检索引用检索图表检索高级检索